Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.47 HKD | 0.00% |
|
-7.49% | -63.94% |
06/06 | ClouDr Group Limited Announces Resignation of Director and Change in Composition of Audit Committee | CI |
05/06 | China Accepts Marketing Application for ClouDr Unit's Vitamin B6 Injection | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company shows low valuation levels, with an enterprise value at 0.23 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-63.94% | 186M | - | ||
-2.26% | 187B | C+ | ||
+2.05% | 110B | C | ||
-1.31% | 69.54B | A | ||
+14.65% | 46.37B | B- | ||
-6.69% | 46.05B | B- | ||
+7.97% | 42.54B | B+ | ||
+18.60% | 30.72B | B | ||
+17.70% | 25.62B | A- | ||
-6.87% | 23.32B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 9955 Stock
- Ratings ClouDr Group Limited